Form 13-F position report

ELICIO THERAPEUTICS INC

Reported by BlackRock Inc

ELTX CUSIP 28657F103 Manager CIK 0001364742

Reported 18,985 shares, up 18,068 (1970.3%) from the prior quarter.

Reported value 1019.7%; share count 1970.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 18,985 Quarter-end amount reported
Reported value $78,029 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-12-31 7648
2024-03-31 6969
2024-06-30 78029
2024-09-30 99056
2024-12-31 101036
2025-03-31 242230
2025-06-30 336260
2025-09-30 483493
2025-12-31 359625
2026-03-31 540882
2026-06-30 2995079
2026-09-30 1347272

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for ELICIO THERAPEUTICS INC held by BlackRock Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 740,259 -25,746 (-3.4%) < 0.01% $1,347,272 2026-11-13
Q2 2026 Added 766,005 +715,408 (1413.9%) < 0.01% $2,995,079 2026-08-07
Q1 2026 Added 50,597 +5,418 (12.0%) < 0.01% $540,882 2026-05-13
Q4 2025 Added 45,179 +984 (2.2%) < 0.01% $359,625 2026-02-12
Q3 2025 Added 44,195 +638 (1.5%) < 0.01% $483,493 2025-11-12
Q2 2025 Added 43,557 +4,234 (10.8%) < 0.01% $336,260 2025-08-12
Q1 2025 Added 39,323 +19,512 (98.5%) < 0.01% $242,230 2025-05-02
Q4 2024 Added 19,811 +118 (0.6%) < 0.01% $101,036 2025-02-07
Q3 2024 New 19,693 +19,693 (0.0%) < 0.01% $99,056 2024-11-13
Q2 2024 Added 18,985 +18,068 (1970.3%) < 0.01% $78,029 2024-08-13
Q1 2024 Unchanged 917 0 (0.0%) < 0.01% $6,969 2024-05-10
Q4 2023 New 917 +917 (0.0%) < 0.01% $7,648 2024-02-13

Who else reported the position

24 managers reported ELICIO THERAPEUTICS INC for Q2 2024.

Managers reporting ELICIO THERAPEUTICS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 226,297 +10,611 < 0.01% $930,080 5 qtrs
ARMISTICE CAPITAL LLC New 100,000 +100,000 < 0.01% $411,000 1 qtr
GEODE CAPITAL MANAGEMENT LLC Added 71,508 +23,812 < 0.01% $293,930 5 qtrs
CM Management LLC Reduced 50,000 -25,000 0.19% $205,500 5 qtrs
Arena Investors LP New 50,000 +50,000 1.64% $205,500 1 qtr
Hudson Bay Capital Management LP New 48,720 +48,720 < 0.01% $200,239 1 qtr
STATE STREET CORPORATION Added 21,900 +4,300 < 0.01% $90,009 2 qtrs
BlackRock Inc This report Added 18,985 +18,068 < 0.01% $78,029 3 qtrs
MEYER HANDELMAN CO Unchanged 13,899 0 < 0.01% $57,125 5 qtrs
BRIDGEWAY CAPITAL MANAGEMENT LLC Unchanged 12,500 0 < 0.01% $51,375 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
18,985
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.